[go: up one dir, main page]

SV2008002929A - Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia - Google Patents

Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia

Info

Publication number
SV2008002929A
SV2008002929A SV2008002929A SV2008002929A SV2008002929A SV 2008002929 A SV2008002929 A SV 2008002929A SV 2008002929 A SV2008002929 A SV 2008002929A SV 2008002929 A SV2008002929 A SV 2008002929A SV 2008002929 A SV2008002929 A SV 2008002929A
Authority
SV
El Salvador
Prior art keywords
chichophrenia
receiver
antagonist
negative symptoms
secondary effects
Prior art date
Application number
SV2008002929A
Other languages
English (en)
Inventor
Mark Black
Beth Borowsky
Nancy Rogacki
Yaw Senyah
Rachel Stevens
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of SV2008002929A publication Critical patent/SV2008002929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRIBE Y REIVINDICA UN MÉTODO PARA TRATAR DÉFICITSCOGNITIVOS EN UN PACIENTE QUE PADECE ESQUIZOFRENIA, MEDIANTE LA ADMINISTRACIÓN ADICHO PACIENTE DE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN ANTAGONISTA DEL RECEPTORCB1 COMO SE DESCRIBE EN ESTA MEMORIA. EN OTRO ASPECTO, ESTA INVENCIÓN TAMBIÉNDESCRIBE Y REIVINDICA UNA COMBINACIÓN DE UNO O MÁS ANTAGONISTAS DEL RECEPTOR CB1 YDE UNO O MÁS AGENTES ANTIPSICÓTICOS ÚTILES EN EL TRATAMIENTO DE TRASTORNOS PSIQUIÁTRICOS.LA COMBINACIÓN DE ESTA INVENCIÓN PROPORCIONA RESULTADOS SINÉRGICOS EN LOS QUE LACOMBINACIÓN MEJORA LOS SÍNTOMAS POSITIVOS Y NEGATIVOS DE LA ESQUIZOFRENIA, LA GANANCIADE PESO Y LA CATALEPSIA
SV2008002929A 2005-12-08 2008-06-06 Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia SV2008002929A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74843405P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
SV2008002929A true SV2008002929A (es) 2009-12-02

Family

ID=37964962

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002929A SV2008002929A (es) 2005-12-08 2008-06-06 Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia

Country Status (23)

Country Link
US (1) US20080221078A1 (es)
EP (1) EP1962834A2 (es)
JP (1) JP2009518423A (es)
KR (1) KR20080073737A (es)
CN (1) CN101321523A (es)
AR (1) AR056846A1 (es)
AU (1) AU2006321907A1 (es)
BR (1) BRPI0619541A2 (es)
CA (1) CA2632673A1 (es)
CR (1) CR9957A (es)
DO (1) DOP2006000273A (es)
EC (1) ECSP088505A (es)
IL (1) IL191888A0 (es)
MA (1) MA30090B1 (es)
NO (1) NO20082923L (es)
PE (1) PE20071092A1 (es)
RU (1) RU2008127491A (es)
SV (1) SV2008002929A (es)
TN (1) TNSN08205A1 (es)
TW (1) TW200803839A (es)
UY (1) UY29995A1 (es)
WO (1) WO2007067617A2 (es)
ZA (1) ZA200803924B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2700974A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
PE20091270A1 (es) * 2007-12-18 2009-09-23 Sanofi Aventis Derivados de azetidinas con actividad sobre receptores cb1 y su preparacion
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
SG11201701598PA (en) * 2014-09-10 2017-03-30 Epizyme Inc Smyd inhibitors
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
PT3504187T (pt) 2016-08-24 2025-05-09 Prilenia Neurotherapeutics Ltd Utilização da pridopidina no tratamento do declínio funcional

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
EP1636181A1 (en) * 2003-06-11 2006-03-22 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique

Also Published As

Publication number Publication date
WO2007067617A3 (en) 2007-11-01
MA30090B1 (fr) 2008-12-01
NO20082923L (no) 2008-09-02
US20080221078A1 (en) 2008-09-11
EP1962834A2 (en) 2008-09-03
PE20071092A1 (es) 2007-12-10
RU2008127491A (ru) 2010-01-20
AR056846A1 (es) 2007-10-24
AU2006321907A1 (en) 2007-06-14
DOP2006000273A (es) 2007-10-15
BRPI0619541A2 (pt) 2011-10-04
CN101321523A (zh) 2008-12-10
JP2009518423A (ja) 2009-05-07
IL191888A0 (en) 2009-08-03
ECSP088505A (es) 2008-08-29
TNSN08205A1 (en) 2009-10-30
ZA200803924B (en) 2009-10-28
UY29995A1 (es) 2007-07-31
CR9957A (es) 2008-09-22
KR20080073737A (ko) 2008-08-11
TW200803839A (en) 2008-01-16
CA2632673A1 (en) 2007-06-14
WO2007067617A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
SV2008002929A (es) Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CL2012000591A1 (es) Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.
ECSP067116A (es) Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
MX370000B (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3.
PA8620501A1 (es) Compuestos utiles en terapia
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
MX2017005940A (es) Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
CL2007001555A1 (es) Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
EA200970303A1 (ru) Тиазолпиразолопиримидин в качестве антагониста рецептора крф1
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CR10139A (es) "combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfusión congnitiva"
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
AR057239A1 (es) Inmunoglobulinas
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten

Legal Events

Date Code Title Description
FD Lapse